Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial
NCT05379153
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This phase III trial compares the effect of vaginal fractional CO2 laser therapy to placebo for the treatment of vaginal dryness in breast cancer survivors with symptoms of genitourinary syndrome of menopause (GSM). Placebo therapy is an inactive treatment that is designed to mimic as closely as possible the active treatment being studied in a clinical trial. In this trial, patients will not be told whether they will be in the laser treatment group or the placebo group until 6-weeks after the third treatment visit (patient-blinded).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Vaginal Atrophy
- Breast Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 22 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Alliance for Clinical Trials in Oncology
- Last updated on ClinicalTrials.gov
- September 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- Trinity Health IHA - Obstetrics and Gynecology West Arbor · Ann Arbor, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.